First slide
Sureseq Logo

Product summary

  • Technology NGS
  • Application Haematology
  • Areas of interest AML
  • Gene Targets 1 - 29+
  • Aberration Types SNV, indel, ITD, PTD, translocation
  • Product Code Various
  • Regulatory Status For research use only; not for diagnostic procedures.



Acute myeloid leukaemia (AML) is the most common type of acute leukaemia in adults. Our understanding of AML has been transformed in recent years to a disease classified largely based on genetic, genomic and molecular characteristics. Key genes implicated in AML progression include CEBPA, NPM1, FLT3 and KMT2A (MLL) with mutations in multiple additional genes identified in recent research1.

Choose your perfect AML NGS panel from our range of fully tested and optimised panel content. Simply mix and match the genes or individual exons you require for your research and get the most out of your sequencing runs.

Getting started with your SureSeq myPanel™ NGS Custom Panel could not be simpler, find out more in this video…

  • Unparalleled coverage uniformity across all content including CEBPA — confidently detect AML variants and remove the requirement for supplementary fill-in approaches
  • Bespoke panels with pre-optimised content — create your ideal AML panel and sequence only what’s relevant for your AML research
  • Robust detection of FLT3-ITDs and KMT2A-PTDs — streamline your laboratory workflow with a single NGS assay for comprehensive aberration detection in AML
  • Complimentary Interpret NGS data analysis software — easy-to-use analysis solution for accurate detection of all variants

Gene targets

Select a gene to view exon coverage examples:

* Exon examples not yet available

Want to customise these gene targets?

We have a regularly updated, expert-curated library of pre-optimised cancer panel content for you to select from. Simply mix and match the gene, exonic or intronic content you need to create an AML NGS cancer panel that meets your exact requirements.


Excellent coverage uniformity of the CEBPA gene

Mutations in the CEBPA gene are among the most common molecular alterations in AML. Sequencing of CEBPA is challenging due to the presence of repeat regions and the high GC-content of the gene, leading to poor coverage across these regions and potentially missed variants. OGT’s expert bait design overcomes these issues and provides exceptional coverage uniformity, even in difficult to sequence genes, enabling reliable detection of variants and eliminating the requirement for supplementary fill-in with Sanger sequencing (Figure 1).

Sophisticated bait design strategies allowing reliable FLT3-ITD and KMT2A-PTD detection

The most prevalent type of FLT3 mutations in AML are internal tandem duplications (ITDs). FLT3-ITDs are challenging to target because they are by nature repetitive and can be very long. As a result, FLT3- ITDs are generally masked in most panel designs, necessitating additional techniques to generate a complete picture of the genetic makeup of AML. To provide optimal results OGT employs sophisticated bait design strategies to generate uniform coverage across, as well as upstream and downstream of the repetitive region, allowing easy detection of FLT3-ITDs ranging from a handful of base pairs to >200 bp (Figure 2).

Other tandem duplications frequently observed in AML are partial tandem duplications (PTDs) in KMT2A (MLL). Similar to ITDs, KMT2A-PTDs are notoriously difficult to detect due to their size, with duplications spanning exons 3 to 9, exons 3 to 10 and exons 3 to 11 being the most commonly found in AML2. With OGT’s expertise in hybridisation-based panel design, your SureSeq myPanel offers robust detection of all sizes of KMT2A-PTDs, alleviating the burden of running multiple assays (Figure 3).

Complimentary Interpret NGS analysis software

Interpret is OGT’s powerful and easy-to-use data analysis solution, facilitating analysis and visualisation of a wide range of somatic variants and structural aberrations. Designed to work seamlessly with all SureSeq™ panels, you’ll be able to accurately detect all SNVs, indels, ITDs and PTDs covered by your SureSeq myPanel Custom AML Panel. Additionally, if you choose to expand your panel further, our Interpret software can reliably detect copy-number variations (CNVs), loss-of-heterozygosity (LOH) and translocations, for example BCR-ABL. Following detection, all variants can be readily visualised in the user-friendly variant browser, for an effortless translation of all your AML data into meaningful results.

SureSeq myPanel NGS Custom AML panel workflow

Content selection Image

Content selection

Sure Seq Bar 1
  • SureSeq myPanel NGS Custom AML panel


  1. Döhner et al., Blood 2017; 129(4):424–447
  2. Steudel et al., Genes Chromosomes Cancer 2003; 37(3):237-51

Request a quote for this product

View all products

NGS resources & support